Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

키워드

참고문헌 (71)

1. Yip TC, "Geographical similarity and differences in the burden and genetic predisposition of NAFLD", Hepatology (2022)[DOI]
2. Gwyneth Soon, "Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective", Clinical and Molecular Hepatology, 27(1), pp.44~57 (2021), 대한간학회[DOI]
3. Ekstedt M, "Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
4. Le P, "Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies", Clin Gastroenterol Hepatol (2022)[DOI]
5. Wong VW, "Pathogenesis and novel treatment options for non-alcoholic steatohepatitis", Lancet Gastroenterol Hepatol, 1, pp.56~67 (2016)
6. Leung HH, "Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems", J Gastroenterol Hepatol, 37, pp.1131~1138 (2022)
7. Davison BA, "Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials", J Hepatol, 73, pp.1322~1332 (2020)
8. Brunt EM, "NAFLD : reporting histologic findings in clinical practice", Hepatology, 73, pp.2028~2038 (2021)
9. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
10. Brunt EM, "Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
11. Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients", Hepatology, 56, pp.1751~1759 (2012)
12. Bedossa P, "Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis, activity, and fibrosis(SAF)score in the evaluation of biopsies of nonalcoholic fatty liver disease", Hepatology, 60, pp.565~575 (2014)
13. Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
14. Pai RK, "Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score", Hepatology, 76, pp.1150~1163 (2022)
15. Wong VW, "Noninvasive biomarkers in NAFLD and NASH-current progress and future promise", Nat Rev Gastroenterol Hepatol, 15, pp.461~478 (2018)
16. Piazzolla VA, "Noninvasive diagnosis of NAFLD and NASH", Cells, 9, pp.1005~ (2020)
17. Zeng Y, "Advance of serum biomarkers and combined diagnostic panels in nonalcoholic fatty liver disease", Dis Markers, 2022, pp.1254014~ (2022)
18. Shen J, "Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers", J Hepatol, 56, pp.1363~1370 (2012)
19. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]
20. Masoodi M, "Metabolomics and lipidomics in NAFLD : biomarkers and non-invasive diagnostic tests", Nat Rev Gastroenterol Hepatol, 18, pp.835~856 (2021)
21. Alonso C, "Metabolomic identification of subtypes of nonalcoholic steatohepatitis", Gastroenterology, 152, pp.1449~1461 (2017)
22. Ferraioli G, "Quantification of liver fat content with ultrasound : a WFUMB position paper", Ultrasound Med Biol, 47, pp.2803~2820 (2021)
23. European Association for the Study of the Liver(EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
24. Hernaez R, "Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver : a meta-analysis", Hepatology, 54, pp.1082~1090 (2011)
25. Charatcharoenwitthaya P, "Role of radiologic modalities in the management of non-alcoholic steatohepatitis", Clin Liver Dis, 11, pp.37~54 (2007)
26. Bril F, "Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients", Liver Int, 35, pp.2139~2146 (2015)
27. Hamaguchi M, "The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation", Am J Gastroenterol, 102, pp.2708~2715 (2007)
28. Ballestri S, "Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD", Liver Int, 32, pp.1242~1252 (2012)
29. Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
30. Lee HW, "Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease", PLoS One, 11, pp.e0157358~ (2016)
31. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607 (2017)
32. Alkhouri N, "Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis : a randomised, open-label phase II trial", J Hepatol, 77, pp.607~618 (2022)
33. Younossi ZM, "The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis", Gastroenterology, 160, pp.1608~1619 (2021)
34. Newsome PN, "FibroScan-AST(FAST)score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
35. Woreta TA, "Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis(NASH)in a North American cohort and comparison to other non-invasive algorithms", PLoS One, 17, pp.e0266859~ (2022)
36. Cardoso AC, "Validation and performance of FibroScan®-AST(FAST)score on a Brazilian population with nonalcoholic fatty liver disease", Dig Dis Sci, 67, pp.5272~5279 (2022)
37. Vilalta A, "Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD", NASH, 2022, pp.5, e00335~
38. Vernuccio F, "Advances in liver US, CT, and MRI : moving toward the future", Eur Radiol Exp, 5, pp.52~ (2021)
39. Naganawa S, "Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis", Eur Radiol, 28, pp.3050~3058 (2018)
40. McDonald N, "Multiparametric magnetic resonance imaging for quantitation of liver disease : a two-centre cross-sectional observational study", Sci Rep, 8, pp.9189~ (2018)
41. Andersson A, "Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression : a multicenter pooled data and meta-analysis", Clin Gastroenterol Hepatol, 20, pp.2451~2461 (2022)
42. Pavlides M, "Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease", J Hepatol, 64, pp.308~315 (2016)
43. Jayakumar S, "Longitudinal correlations between MRE, MRIPDFF, and liver histology in patients with non-alcoholic steatohepatitis : analysis of data from a phase II trial of selonsertib", J Hepatol, 70, pp.133~141 (2019)
44. Tamaki N, "Clinical utility of 30% relative decline in MRIPDFF in predicting fibrosis regression in non-alcoholic fatty liver disease", Gut, 71, pp.983~990 (2022)
45. Jung J, "MRE combined with FIB-4(MEFIB)index in detection of candidates for pharmacological treatment of NASH-related fibrosis", Gut, 70, pp.1946~1953 (2021)
46. Tamaki N, "Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis", Hepatology, 75, pp.661~672 (2022)
47. Kim BK, "Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD", J Hepatol, 77, pp.1482~1490 (2022)
48. Ajmera V, "Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease : a systematic review and meta-analysis of individual participants", Gastroenterology, 163, pp.1079~1089 (2022)
49. Noureddin M, "MRI-based(MAST)score accurately identifies patients with NASH and significant fibrosis", J Hepatol, 76, pp.781~787 (2022)
50. Allen AM, "The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery", Hepatology, 71, pp.510~521 (2020)
51. Allen AM, "Multiparametric magnetic resonance elastography improves the detection of NASH regression following bariatric surgery", Hepatol Commun, 4, pp.185~192 (2019)
52. Le Berre C, "Application of artificial intelligence to gastroenterology and hepatology", Gastroenterology, 158, pp.76~94 (2020)
53. Fialoke S, "Application of machine learning methods to predict non-alcoholic steatohepatitis(NASH)in non-alcoholic fatty liver(NAFL)patients", AMIA Annu Symp Proc, 2018, pp.430~439 (2018)
54. Docherty M, "Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis", J Am Med Inform Assoc, 28, pp.1235~1241 (2021)
55. Canbay A, "Non-invasive assessment of NAFLD as systemic disease-a machine learning perspective", PLoS One, 14, pp.e0214436~ (2019)
56. Perakakis N, "Non-invasive diagnosis of nonalcoholic steatohepatitis and fibrosis with the use of omics and supervised learning : a proof of concept study", Metabolism, 101, pp.154005~ (2019)
57. Vandromme M, "Automated phenotyping of patients with non-alcoholic fatty liver disease reveals clinically relevant disease subtypes", Pac Symp Biocomput, 25, pp.91~102 (2020)
58. Liu F, "qFIBS : an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis", Hepatology, 71, pp.1953~1966 (2020)
59. Esteva A, "A guide to deep learning in healthcare", Nat Med, 25, pp.24~29 (2019)
60. Taylor-Weiner A, "A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH", Hepatology, 74, pp.133~147 (2021)
61. Heinemann F, "Deep learning enables pathologist-like scoring of NASH models", Sci Rep, 9, pp.18454~ (2019)
62. Jana A, "Deep Learning based NAS Score and Fibrosis Stage Prediction from CT and Pathology Data", 2020 Ieee 20th International Conference on Bioinformatics and Bioengineering (Bibe 2020), pp.981~986 (2020)
63. Wu Z, "A comprehensive survey on graph neural networks", IEEE Trans Neural Netw Learn Syst, 32, pp.4~24 (2021)
64. Jaume G, "Quantifying Explainers of Graph Neural Networks in Computational Pathology", 2021 Ieee, 2021, 8102~8112
65. Dwivedi C, "Multi stain graph fusion for multimodal integration in pathology", 2021 Ieee, 2021, 1835~1845
66. Tan Q, "Explainable uncertainty-aware convolutional recurrent neural network for irregular medical time series", IEEE Trans Neural Netw Learn Syst, 32, pp.4665~4679 (2021)
67. Tan Q, "Cooperative joint attentive network for patient outcome prediction on irregular multi-rate multivariate health data", Proceedings of the Thirtieth International Joint Conference on Artificial Intelligence: International Joint Conferences on Artificial Intelligence Organization, pp.1586~1592 (2021)
68. Suresha PB, "Explainable AI in Healthcare and Medicine", pp.107~113 (2021), Springer International Publishing
69. Yin C, "Learning Sparse Interpretable Features For NAS Scoring From Liver Biopsy Images", Proceedings of the Thirty-First International Joint Conference on Artificial Intelligence: International Joint Conferences on Artificial Intelligence Organization, pp.1580~1586 (2022)
70. Yin C, "Medical Image Computing and Computer Assisted Intervention - MICCAI 2021", pp.153~162 (2021), Springer International Publishing
71. Lyu F, "Weakly supervised liver tumor segmentation using couinaud segment annotation", IEEE Trans Med Imaging, 41, pp.1138~1149 (2022)

관련 논문AI추천